Corrigendum to “Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis” [EClinicalMedicine 55 (2022) 101795]
Zhiwen Fu,
Jinmei Liu,
Shijun Li,
Chen Shi,
Yu Zhang
Affiliations
Zhiwen Fu
Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Province Clinical Research Centre for Precision Medicine for Critical Illness
Jinmei Liu
Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Province Clinical Research Centre for Precision Medicine for Critical Illness
Shijun Li
Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Province Clinical Research Centre for Precision Medicine for Critical Illness
Chen Shi
Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Province Clinical Research Centre for Precision Medicine for Critical Illness; Corresponding author. Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei Province, China, 430000
Yu Zhang
Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Province Clinical Research Centre for Precision Medicine for Critical Illness; Corresponding author. Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei Province, China, 430000